New Two-Drug attack tested to shrink breast tumors before surgery
NCT ID NCT07383818
Summary
This study is testing whether a combination of two drugs, trastuzumab rezetecan and toripalimab, can shrink tumors before surgery in people with a specific type of breast cancer (HR-positive, HER2-low). The main goal is to see if the treatment completely eliminates cancer cells in the removed tumor and to monitor side effects. Researchers will also track how long patients remain cancer-free after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR POSITIVE/HER2 LOW BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact
-
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi'an, China
Contact
-
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGZhengzhou, China
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, China
Contact
Conditions
Explore the condition pages connected to this study.